Lessons from natural molecules

By Jon Clardy, C. Walsh. Nature, 2004

1,069 citations recorded by the source corpus.

Subfields: Biotechnology, Organic Chemistry, Pharmacology

View Paper: https://www.semanticscholar.org/paper/d2295763741d2e7330f2e6da84f1f998b61a8dce

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biotechnology

1. D. Newman
2. G. Cragg
3. M. Gordaliza
4. Kim Lewis
5. C. Walsh
6. Jon Clardy
7. T. Maoka
8. A. Harvey

In Organic Chemistry

1. M. Gordaliza
2. G. Cragg
3. D. Newman
4. Kim Lewis
5. W. Fenical
6. P. Jensen
7. C. Walsh
8. A. Kinghorn

In Pharmacology

1. G. Cragg
2. D. Newman
3. M. Gordaliza
4. Kim Lewis
5. Michael A. Fischbach
6. Jon Clardy
7. C. Walsh
8. P. Jensen

Citations in the corpus

• Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review (2014, background): “Natural products possess a high chemical scaffold diversity and are evolutionary optimized to serve different biological functions, conferring them a high drug-likeness and making them an excellent source for identification of new drug leads [117–119].”
• Natural products as leads to anticancer drugs (2007, background): “Natural compounds offer huge structural diversity and in some cases great biological potency [28].”
• NATURAL PRODUCTS: A CONTINUING SOURCE OF NOVEL DRUG LEADS (2013, background): “The rapid developments in the analysis of microbial genomes has enabled the identification of a multitude of gene clusters encoding for polyketides, NRPs and hybrid polyketide-NRP metabolites, and have provided the tools for engineering the biosynthesis of novel “non-natural” natural products throug”
• New antibiotics from bacterial natural products (2006, background): “Although more information on abyssomicin's mode of action is clearly required, its discovery reinforces two messages: first, sampling underexplored biological niches leads to detection of new natural product framework”
• Multidrug tolerance of biofilms and persister cells. (2008, background): “The crisis nonetheless looms, caused by a conspicuous lack of novel classes of broad-spectrum antibiotics in the face of growing drug resistance (Dougherty et al. 2002; Boggs and Miller 2004; Bush 2004; Clardy and Walsh 2004; Projan and Shlaes 2004; Schmid 2004; Silver 2006).”
• MassBank: a public repository for sharing mass spectral data for life sciences. (2010, background): “In the life sciences, different types of mass spectrometers are used to analyze chemical compounds in biological samples because their diverse chemical structure results in different physicochemical properties.[8,9] For example, in most metabolomics studies, GC and LC are coupled to EI-MS and ESI-MS”
• Drug discovery from medicinal plants. (2005, background): “, chiral centers, aromatic rings, complex ring systems, degree of molecule saturation, and number and ratio of heteroatoms) have been shown to be highly relevant to drug discovery efforts (Lee and Schneider, 2001; Feher and Schmidt, 2003; Clardy and Walsh, 2004; Piggott and Karuso, 2004; Koehn and C”
• Developing a new resource for drug discovery: marine actinomycete bacteria (2006, background): “Yet like many trends, concepts in drug discovery that were once considered passe have reemerged in a new light, and the unique structural diversity inherent to natural products is again being recognized for its value to the drug discovery proces”
• Discovery and resupply of pharmacologically active plant-derived natural products: A review (2015, background): “…biological actions due to binding affinities for specific proteins relevant for their biological functions, possess superior chemical diversity and complexity developed during biosynthesis (Clardy and Walsh, 2004; Koehn and Carter, 2005), and often have more advantageous ADME/T properties.”